Alan F. Denenberg

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior…

Davis Polk advised Shockwave Medical, Inc. in connection with a $16.5 million supplemental term loan provided by Silicon Valley Bank. Shockwave Medical used a portion of the proceeds…

Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by Theravance Biopharma, Inc. Theravance Biopharma’s ordinary shares…

Davis Polk advised the joint book-running managers in connection with a $2.25 billion SEC-registered debt offering by Intel Corporation. The offering consisted of $750 million…

Davis Polk advised SMART Global Holdings, Inc. in connection with a Rule 144A offering of $250 million aggregate principal amount of its 2.25% convertible senior notes due 2026. Davis Polk…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $281.75 million initial public offering by 1Life Healthcare, Inc…

Davis Polk advised the underwriters in connection with Alector, Inc.’s $240 million public offering of 9,602,500 shares of common stock, which includes the 1,252,500 shares offered pursuant…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $207 million public offering of common stock of Denali Therapeutics,…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Autodesk, Inc. of $500 million aggregate principal amount of its 2.850% senior notes due…